Alkermes reported positive Phase 2 trial results for its orexin receptor agonist alixorexton in narcolepsy type 1 patients, showing statistically significant improvements in wakefulness and reduced daytime sleepiness across multiple doses. The drug aims to address orexin deficiency, a key condition in narcolepsy, and compete with Takeda’s late-stage candidate. While only the mid-dose significantly reduced cataplexy events, Alkermes plans to refine measurements in upcoming Phase 3 trials. No serious safety signals emerged.